Your activity: 4 p.v.

Dapagliflozin: Drug information

Dapagliflozin: Drug information
(For additional information see "Dapagliflozin: Patient drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)
Brand Names: US
  • Farxiga
Brand Names: Canada
  • Forxiga
Pharmacologic Category
  • Antidiabetic Agent, Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor;
  • Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor
Dosing: Adult

Note: Hypovolemia, if present, should be corrected prior to initiating therapy. May require a gradual dose reduction of insulin and/or insulin secretagogues (sulfonylureas, meglitinides) to avoid hypoglycemia (Ref).

Chronic kidney disease

Chronic kidney disease (adjunctive agent):

Note: May be used as a secondary agent in patients with persistently elevated urinary albumin excretion (urine albumin-to-creatinine ratio 200 to 5,000 mg/g) who are receiving other first-line therapies. Benefits were consistently demonstrated in patients with or without type 2 diabetes (Ref).

Oral: 10 mg once daily (Ref).

Diabetes mellitus, type 2, treatment

Diabetes mellitus, type 2, treatment:

Note: May be used as an adjunctive agent or alternative monotherapy for patients in whom initial therapy with lifestyle intervention and metformin failed or those who cannot take metformin. May be preferred in patients with atherosclerotic cardiovascular disease (ASCVD), heart failure, or diabetic kidney disease given demonstrated cardiovascular and renal benefits (Ref).

Hyperglycemia: Oral: Initial: 5 mg once daily; may increase to 10 mg once daily after 4 to 12 weeks if needed to achieve glycemic goals (Ref).

Heart failure: Note: In patients with type 2 diabetes mellitus and established ASCVD, multiple risk factors for ASCVD, or heart failure with reduced ejection fraction, dapagliflozin has been shown to reduce the risk of heart failure hospitalization (Ref). In patients with type 2 diabetes mellitus and heart failure with reduced ejection fraction, dapagliflozin has also been shown to reduce the risk of cardiovascular death (Ref).

Oral: 10 mg once daily (Ref).

Diabetic kidney disease: Note: Studies showing renal benefit were conducted in patients with severely increased albuminuria (eg, urinary albumin excretion >300 mg/day) (Ref). Some experts also use dapagliflozin in patients without severely increased albuminuria; benefits and harms may be more closely balanced due to smaller absolute benefit (Ref). Because SGLT2 inhibitors have less glycemic benefit as eGFR declines, another agent may be needed to achieve glycemic goals (Ref).

Oral: 10 mg once daily (Ref).

Heart failure with reduced ejection fraction

Heart failure with reduced ejection fraction:

Note: Should be considered for use in combination with other evidence-based therapies as part of an optimal medical regimen for heart failure with reduced ejection fraction (Ref). Benefits were consistently demonstrated in patients with or without type 2 diabetes (Ref).

Oral: 10 mg once daily (Ref).

Heart failure with preserved ejection fraction

Heart failure with preserved ejection fraction (off-label use):

Note: Should be considered for use in combination with other evidence-based therapies (Ref). Benefits were demonstrated in patients with or without type 2 diabetes (Ref).

Oral: 10 mg once daily (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.

Altered kidney function:

eGFR ≥45 mL/minute/1.73 m2: No dosage adjustment necessary.

eGFR 25 to <45 mL/minute/1.73 m2:

Chronic kidney disease: No dosage adjustment necessary.

Diabetes mellitus, type 2:

Hyperglycemia: The US manufacturer does not recommend use; recommendations regarding indicated level of eGFR for initiation or continued use may vary in other countries (Ref).

Heart failure: No dosage adjustment necessary.

Diabetic kidney disease: No dosage adjustment necessary.

Heart failure with reduced ejection fraction: No dosage adjustment necessary.

eGFR <25 mL/minute/1.73 m2:

Chronic kidney disease: The manufacturer's labeling does not recommend initiation of therapy; however, patients previously established on dapagliflozin may continue 10 mg once daily.

Diabetes mellitus, type 2:

Hyperglycemia: The US manufacturer does not recommend use.

Heart failure: The manufacturer's labeling does not recommend initiation of therapy; however, patients previously established on dapagliflozin may continue 10 mg once daily.

Diabetic kidney disease: The manufacturer's labeling does not recommend initiation of therapy; however, patients previously established on dapagliflozin may continue 10 mg once daily.

Heart failure with reduced ejection fraction: The manufacturer's labeling does not recommend initiation of therapy; however, patients previously established on dapagliflozin may continue 10 mg once daily.

Hemodialysis, intermittent (thrice weekly): Use is contraindicated (Ref).

Peritoneal dialysis: Use is contraindicated (Ref).

CRRT: Avoid use (Ref).

PIRRT (eg, sustained, low-efficiency diafiltration): Avoid use (Ref).

Dosing: Hepatic Impairment: Adult

No dosage adjustment necessary; use caution if initiating in severe impairment (has not been studied).

Dosing: Older Adult

Refer to adult dosing.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Tablet, Oral:

Farxiga: 5 mg, 10 mg

Generic Equivalent Available: US

No

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Tablet, Oral:

Forxiga: 5 mg, 10 mg

Medication Guide and/or Vaccine Information Statement (VIS)

An FDA-approved patient medication guide, which is available with the product information and at https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202293s028lbl.pdf#page=52, must be dispensed with this medication.

Administration: Adult

Oral: Administer in the morning with or without food.

Use: Labeled Indications

Chronic kidney disease: To reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease at risk of progression.

Limitations of use: Dapagliflozin is not recommended in patients with polycystic kidney disease, or in those who currently require or with a recent history of immunosuppressive therapy for kidney disease.

Diabetes mellitus, type 2, treatment: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus; risk reduction of hospitalization for heart failure in patients with type 2 diabetes mellitus and established cardiovascular disease or multiple cardiovascular risk factors.

Heart failure with reduced ejection fraction: To reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure with reduced ejection fraction (NYHA class II to IV).

Use: Off-Label: Adult

Heart failure with preserved ejection fraction

Medication Safety Issues
Sound-alike/look-alike issues:

Farxiga has been confused with Fetzima

Adverse Reactions (Significant): Considerations
Acute kidney injury

Cases of acute kidney injury (AKI) have been reported in patients receiving sodium-glucose cotransporter 2 (SGLT2) inhibitors (specifically canagliflozin and dapagliflozin), including cases that have required hospitalization and dialysis (Ref). While dapagliflozin may cause reversible kidney-related adverse events (eg, increased serum creatinine, decreased estimated GFR [eGFR]) during the first 2 weeks of therapy, the DAPA-CKD trial showed an overall reduction in the risk of sustained decline in the eGFR ≥50%, end-stage kidney disease, or death from renal or cardiovascular outcomes in patients who received dapagliflozin (Ref). A post hoc analysis of the DAPA-CKD trial found that patients who had acute reductions in eGFR >10% after 2 weeks of dapagliflozin therapy had slower rates of long-term eGFR decline compared with patients who experienced a less pronounced decline or increase in eGFR, suggesting an acute reduction in eGFR with dapagliflozin initiation is not associated with higher rates of chronic kidney disease progression (Ref) . As evidence mounts for the positive effects of these agents on long-term kidney outcomes and a possible reduction in the incidence of AKI with dapagliflozin specifically, clinicians will need to weigh the potential risk of AKI with the overall benefit of these agents (Ref).

Mechanism: Dose-related; related to the pharmacologic action. SGLT2 inhibition causes increased excretion of glucose and sodium, thereby resulting in an osmotic diuresis; the subsequent hyperosmolarity and volume contraction may increase the risk of AKI. Glucose in the urine may be reabsorbed by glucose transporters in exchange for uric acid, resulting in uricosuria and associated crystal-dependent and -independent damage. Lastly, SGLT2 inhibition results in increased fructose generation; the metabolism of fructose may lead to increased uric acid, oxidative stress, and the release of chemokines, thus causing local tubular injury and inflammation (Ref).

On the other hand, dapagliflozin may confer some protection against AKI. Proposed mechanisms based on animal studies regarding the beneficial effects of SGLT2 inhibition on AKI include improved kidney cortical oxygen tension, tubular cell integrity, and tubular albumin reabsorption (Ref); in addition, improved cardiac function may be related to improved kidney function (Ref).

Onset: Varied. With regard to decreases in eGFR, in the DAPA-CKD study, administration of dapagliflozin caused early decline in eGFR which tended to stabilize after ~4 weeks (Ref).

Risk factors:

• Preexisting risk factors for AKI (eg, hypovolemia, chronic kidney insufficiency, heart failure, use of concomitant medications [eg, diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, nonsteroidal anti-inflammatory drugs])

Bone fractures

An increased incidence of bone fractures occurred in patients with type 2 diabetes mellitus and moderate renal impairment (eGFR 30 to 60 mL/minute/1.73 m2) in one randomized controlled trial (Ref); however, a second randomized controlled trial did not confirm a similar increased risk in patients with type 2 diabetes mellitus and eGFR 45 to 60 mL/minute/1.73 m2 (Ref). In the overall population, dapagliflozin does not appear to increase risk of fractures, though longer-term data may be necessary to clarify risk (Ref).

Hypersensitivity

Hypersensitivity reactions, including angioedema, urticaria, anaphylaxis, and skin rash, have been reported in patients receiving sodium-glucose cotransporter 2 (SGLT2) inhibitors (Ref).

Mechanism: Not clearly established. Multiple potential mechanisms including:

Non–dose-related; immunologic: IgE-mediated or direct mast cell stimulation (Ref)

Dose-related; related to the pharmacologic action: Elevated levels of bradykinin (Ref)

Onset: Varied; generally occurs hours to days after treatment initiation.

Risk factors:

• Prior serious hypersensitivity reaction to canagliflozin

• Cross-reactivity: Although other SGLT2 have also been associated with hypersensitivity reactions, there are no reports of cross-reactions between these agents

Hypotension/volume depletion

Sodium-glucose cotransporter 2 (SGLT2) inhibitors may cause events consistent with hypovolemia, including symptomatic hypotension, syncope, and dehydration (Ref). Overall, a reduction in both systolic and diastolic blood pressure (-4 to -6/-1 to -2 mm Hg) has been documented for SGLT2 inhibitors (Ref).

Mechanism: Dose-related; related to the pharmacologic action. Inhibition of SGLT2 causes an increase in the excretion of glucose and sodium, thereby resulting in an osmotic diuresis and intravascular volume contraction (Ref).

Onset: Varied; timing is impacted by volume status (eg, reduced oral intake, fluid losses) and concomitant use of medications known to impact volume status or blood pressure (eg, diuretics, angiotensin-converting enzyme [ACE] inhibitors, angiotensin receptor blockers [ARBs]) (Ref).

Risk factors:

• Kidney impairment (ie, eGFR <60 mL/minute/1.73 m2)

• Older adults

• Concomitant use of antihypertensives (eg, diuretics, ACE inhibitors, ARBs)

• Preexisting low systolic blood pressure

• Reduced oral intake or increased fluid losses

Infection

Sodium-glucose cotransporter 2 (SGLT2) inhibitors, including canagliflozin, have been associated with an increased risk of genitourinary fungal infection (eg, vulvovaginal mycotic infection, vulvovaginal candidiasis, vulvovaginitis, candida balanitis, balanoposthitis) and, to a lesser extent, urinary tract infections, including severe cases of urinary tract infection with sepsis and pyelonephritis requiring hospitalization (Ref). These events are generally mild in intensity, respond to treatment, and do not lead to discontinuation (Ref). Additionally, rare but serious and potentially fatal cases of necrotizing fasciitis (perineum) (ie, Fournier gangrene) have been reported (Ref).

Mechanism: Dose-related; related to the pharmacologic action. Patients with diabetes are more prone to urinary tract and genital infections, potentially due to glucosuria-induced bacterial growth, increased adherence of bacteria to the uroepithelium, and altered immune function (Ref). Because SGLT2 inhibitors increase urinary excretion of glucose, it has been hypothesized that these agents further increase the risk of these infections (Ref).

Onset: Varied; available literature suggests that the increased risk of genital infection may be apparent within the first month of SGLT2 inhibitor therapy and remain elevated throughout the course of therapy (Ref); Fournier gangrene may have an average onset of 9 months (range: 5 days to 49 months) (Ref).

Risk factors:

• Diabetes and/or uncontrolled hyperglycemia (Ref)

• Older adults

• Prior history of these types of infections (Ref)

• Females (Ref)

• Uncircumcised males (increased risk for genital infections) (Ref)

Ketoacidosis

Cases of ketoacidosis have been reported in patients with type 1 and type 2 diabetes mellitus receiving sodium-glucose cotransporter 2 (SGLT2) inhibitors, including dapagliflozin (Ref).

In some cases, patients have presented with normal or only modestly elevated blood glucose (<250 mg/dL), which can lead to misdiagnosis, prevent timely initiation of treatment, and negatively influence duration of illness (Ref). In addition, SGLT2 inhibitor-mediated increases in urinary glucose loss may persist for several days after discontinuation which may impact duration of illness in patients who develop ketoacidosis (Ref).

Mechanism: Dose-related; related to the pharmacologic action. Several mechanisms have been proposed centered on increased ketone body production and reabsorption. Because SGLT2 inhibitors decrease urinary excretion of ketone bodies and decrease blood glucose in an insulin-independent manner, plasma glucose and urine ketone concentrations may be lower than what is typically expected in classic presentations of diabetic ketoacidosis (Ref).

Onset: Varied; timing is often impacted by the onset of metabolically stressful events (eg, surgery, extensive exercise, myocardial infarction [MI], stroke, severe infections, prolonged fasting) (Ref).

Risk factors:

• Patients with diabetes who are insulin deficient (eg, latent autoimmune diabetes in adults, type 1 diabetes, some patients with long-standing type 2 diabetes) (Ref)

• Metabolically stressful events (eg, surgery, extensive exercise, MI, stroke, severe infections, prolonged fasting) (Ref)

• Presence of other risk factors that may predispose a patient to ketoacidosis (eg, pancreatic insulin deficiency, dose decreases of insulin, caloric restriction, alcohol abuse, acute febrile illness, surgery, any other extreme stress event)

Lower limb amputation

There are conflicting data involving the risk of lower limb amputations with sodium-glucose cotransporter 2 (SGLT2) inhibitor therapy; canagliflozin, specifically, has been of concern (Ref). Canagliflozin was associated with almost a 2-fold increased risk of lower limb amputations compared to placebo in the CANVAS and CANVAS-R trials, which included patients with type 2 diabetes at high cardiovascular risk (Ref). Trials involving dapagliflozin have not consistently shown an increased risk of lower limb amputation associated with its use (Ref).

Mechanism: Not clearly established (Ref)

Risk factors:

• Preexisting risk factors for amputation (eg, prior amputation, peripheral vascular disease, neuropathy, diabetic foot ulcers, cardiovascular disease) (Ref)

• Age ≥65 years (Ref)

• Lack of preventative foot care

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Incidences are for adults and may include dapagliflozin used as add-on therapy.

1% to 10%:

Endocrine & metabolic: Dyslipidemia (3%), hypovolemia (1% to 3%) (table 1)

Dapagliflozin: Adverse Reaction: Hypovolemia

Drug (Dapagliflozin)

Placebo

Dose

Indication

Number of Patients (Dapagliflozin)

Number of Patients (Placebo)

3%

2%

10 mg/day

Cardiovascular disease

8,574

8,569

1%

0.7%

10 mg/day

Glycemic control

2,360

2,295

0.8%

0.4%

10 mg/day

Glycemic control

1,193

1,393

0.6%

0.4%

5 mg/day

Glycemic control

1,145

1,393

Gastrointestinal: Nausea (3%)

Genitourinary: Dysuria (2%), increased urine output (3% to 4%), urinary tract infection (6%; including pyelonephritis and urinary tract infection with sepsis)

Hematologic & oncologic: Increased hematocrit (1%)

Infection: Genitourinary fungal infection (3% to 8%, including vulvovaginal candidiasis [females] and balanitis [males]) (table 2), influenza (3%)

Dapagliflozin: Adverse Reaction: Genitourinary Fungal Infection

Drug (Dapagliflozin)

Placebo

Population

Dose

Indication

Number of Patients (Dapagliflozin)

Number of Patients (Placebo)

8%

2%

Females

5 mg/day

Glycemic control

1,145

1,393

7%

2%

Females

10 mg/day

Glycemic control

1,193

1,393

3%

0.3%

Males

5 mg/day

Glycemic control

1,145

1,393

3%

0.3%

Males

10 mg/day

Glycemic control

1,193

1,393

Neuromuscular & skeletal: Back pain (4%), limb pain (2%)

Respiratory: Nasopharyngitis (7%)

<1%:

Dermatologic: Severe dermatological reaction

Endocrine & metabolic: Ketoacidosis (including diabetic ketoacidosis and euglycemia ketoacidosis [Leader 2019]) (table 3)

Dapagliflozin: Adverse Reaction: Diabetic ketoacidosis

Drug (Dapagliflozin)

Placebo

Indication

0.3%

0.1%

Cardiovascular disease

Hypersensitivity: Anaphylaxis (severe), angioedema

Frequency not defined:

Endocrine & metabolic: Increased LDL cholesterol

Hypersensitivity: Hypersensitivity reaction

Postmarketing:

Dermatologic: Skin rash, Sweet syndrome (Mattis 2019)

Endocrine & metabolic: Hypercalcemia (Marques Vidas 2018)

Gastrointestinal: Acute pancreatitis (Sujanani 2020)

Hepatic: Hepatic injury (acute-on-chronic-liver failure [Levine 2016])

Infection: Necrotizing fasciitis (perineum) (Elbeddini 2021)

Neuromuscular & skeletal: Bone fracture (Kohan 2014)

Renal: Acute kidney injury (Pleros 2018), decreased estimated GFR (eGFR) (Jongs 2022), increased serum creatinine (Jongs 2022)

Contraindications

History of serious hypersensitivity to dapagliflozin or any component of the formulation; patients on dialysis.

Warnings/Precautions

Disease-related concerns:

• Bariatric surgery:

– Altered absorption: Absorption may be altered given the anatomic and transit changes created by gastric bypass and sleeve gastrectomy surgery (Mechanick 2020; Melissas 2013).

– Dehydration: Evaluate, correct, and maintain postsurgical fluid requirements and volume status prior to initiating therapy and closely monitor the patient for the duration of therapy; volume depletion and related adverse events (eg, hypotension, orthostatic hypotension, syncope) have occurred. Fluid intake may be more difficult after gastric bypass, sleeve gastrectomy, and gastric band (Mechanick 2020).

– Euglycemic diabetic ketoacidosis: Discontinue therapy 3 to 5 days prior to surgery (Bobart 2016). Postoperatively, assess volume status, caloric intake, and need for diabetes treatment and withhold antidiabetic medication if type 2 diabetes is in remission. Ketoacidosis has been reported in patients with type 1 and type 2 diabetes on SGLT2 inhibitors. In some cases, normal or only modestly elevated blood glucose was present (<250 mg/dL) (van Niekerk 2018). Risk factors include significant reduction in insulin, caloric restriction, stress of surgery, and infection.

• Infection, acute: Discontinue therapy if any of the following occur: signs and symptoms of new infection (including osteomyelitis), new pain or tenderness, or sores/ulcers involving the lower limbs (FDA Drug Safety Communication 2017).

• Renal impairment: Glycemic efficacy may be decreased in patients with renal impairment. Assess renal function prior to initiation and as clinically indicated during treatment. The US manufacturer recommends against use for glycemic control in patients with eGFR <45 mL/minute/1.73 m2. Use is contraindicated in all patients on dialysis (regardless of indication).

Special populations:

• Older adults: Older adults may be predisposed to renal impairment or failure.

Other warnings/precautions:

• Appropriate use: Not for use in patients with diabetic ketoacidosis or patients with type 1 diabetes mellitus.

• Hospitalized patients: Use of SGLT2 inhibitors for glycemic control is not routinely recommended for hospitalized patients (ADA 2021).

• Surgical procedures: In patients with diabetes mellitus, consider temporary discontinuation at least 3 days prior to surgery; ensure risk factors for ketoacidosis are resolved prior to reinitiating therapy.

Metabolism/Transport Effects

Substrate of OAT1/3, P-glycoprotein/ABCB1 (minor), UGT1A9; Note: Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.

Alpha-Lipoic Acid: May enhance the hypoglycemic effect of Antidiabetic Agents. Risk C: Monitor therapy

Androgens: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Risk C: Monitor therapy

Beta-Blockers (Beta1 Selective): May enhance the hypoglycemic effect of Antidiabetic Agents. Risk C: Monitor therapy

Beta-Blockers (Nonselective): May enhance the hypoglycemic effect of Antidiabetic Agents. Beta-Blockers (Nonselective) may diminish the therapeutic effect of Antidiabetic Agents. Risk C: Monitor therapy

Bortezomib: May enhance the therapeutic effect of Antidiabetic Agents. Bortezomib may diminish the therapeutic effect of Antidiabetic Agents. Risk C: Monitor therapy

Direct Acting Antiviral Agents (HCV): May enhance the hypoglycemic effect of Antidiabetic Agents. Risk C: Monitor therapy

Etilefrine: May diminish the therapeutic effect of Antidiabetic Agents. Risk C: Monitor therapy

Guanethidine: May enhance the hypoglycemic effect of Antidiabetic Agents. Risk C: Monitor therapy

Hyperglycemia-Associated Agents: May diminish the therapeutic effect of Antidiabetic Agents. Risk C: Monitor therapy

Hypoglycemia-Associated Agents: Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemia-Associated Agents. Risk C: Monitor therapy

Insulins: Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors may enhance the hypoglycemic effect of Insulins. Management: Consider a decrease in insulin dose when initiating therapy with a sodium-glucose cotransporter 2 inhibitor and monitor patients for hypoglycemia. Risk D: Consider therapy modification

Lithium: Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors may decrease the serum concentration of Lithium. Risk C: Monitor therapy

Maitake: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Risk C: Monitor therapy

Monoamine Oxidase Inhibitors: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Risk C: Monitor therapy

Pegvisomant: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Risk C: Monitor therapy

Prothionamide: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Risk C: Monitor therapy

Quinolones: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Quinolones may diminish the therapeutic effect of Agents with Blood Glucose Lowering Effects. Specifically, if an agent is being used to treat diabetes, loss of blood sugar control may occur with quinolone use. Risk C: Monitor therapy

Ritodrine: May diminish the therapeutic effect of Antidiabetic Agents. Risk C: Monitor therapy

Salicylates: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Risk C: Monitor therapy

Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Risk C: Monitor therapy

Sulfonylureas: Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors may enhance the hypoglycemic effect of Sulfonylureas. Management: Consider a decrease in sulfonylurea dose when initiating therapy with a sodium-glucose cotransporter 2 inhibitor and monitor patients for hypoglycemia. Risk D: Consider therapy modification

Thiazide and Thiazide-Like Diuretics: May diminish the therapeutic effect of Antidiabetic Agents. Risk C: Monitor therapy

Reproductive Considerations

Sodium-glucose cotransporter 2 (SGLT2) inhibitors are not recommended for patients with type 2 diabetes mellitus planning to become pregnant. Patients who could become pregnant should use effective contraception during therapy. Transition to a preferred therapy should be initiated prior to conception and contraception should be continued until glycemic control is achieved (ADA 2021; Alexopoulos 2019; Egan 2020)

Pregnancy Considerations

Due to adverse effects on renal development observed in animal studies, the manufacturer does not recommend use of dapagliflozin during the second and third trimesters of pregnancy

Poorly controlled diabetes during pregnancy can be associated with an increased risk of adverse maternal and fetal outcomes, including diabetic ketoacidosis, preeclampsia, spontaneous abortion, preterm delivery, delivery complications, major malformations, stillbirth, and macrosomia. To prevent adverse outcomes, prior to conception and throughout pregnancy, maternal blood glucose and HbA1c should be kept as close to target goals as possible but without causing significant hypoglycemia (ADA 2021; Blumer 2013).

Agents other than dapagliflozin are currently recommended to treat diabetes mellitus in pregnancy (ADA 2021).

Breastfeeding Considerations

It is not known if dapagliflozin is present in breast milk.

Due to the potential for serious adverse reactions in the breastfeeding infant, breastfeeding is not recommended by the manufacturer.

Dietary Considerations

Individualized medical nutrition therapy (MNT) based on ADA recommendations is an integral part of therapy.

Monitoring Parameters

Blood glucose; renal function (baseline and periodically during treatment); monitor for genital mycotic infections and urinary tract infection; monitor for signs/symptoms of necrotizing fasciitis (eg, fever and malaise along with genital or perianal pain, tenderness, erythema, swelling), hypersensitivity reactions; volume status (eg, weight, BP, hematocrit, electrolytes; baseline and periodically during treatment) and signs/symptoms of hypotension; if signs/symptoms of ketoacidosis (eg, nausea/vomiting, abdominal pain, malaise, shortness of breath), confirm diagnosis by direct measurement of blood ketones and arterial pH (measurement of serum bicarbonate or urinary ketones may not be adequate) (AACE [Handelsman 2016]).

HbA1c: Monitor at least twice yearly in patients who have stable glycemic control and are meeting treatment goals; monitor quarterly in patients in whom treatment goals have not been met, or with therapy change. Note: In patients prone to glycemic variability (eg, patients with insulin deficiency), or in patients whose HbA1c is discordant with serum glucose levels or symptoms, consider evaluating HbA1c in combination with blood glucose levels and/or a glucose management indicator (ADA 2021; KDIGO 2020).

Reference Range

Recommendations for glycemic control in patients with diabetes:

Nonpregnant adults (ADA 2021):

HbA1c: <7% (a more aggressive [<6.5%] or less aggressive [<8%] HbA1c goal may be targeted based on patient-specific characteristics). Note: In patients using a continuous glucose monitoring system, a goal of time in range >70% with time below range <4% is recommended and is similar to a goal HbA1c <7%.

Preprandial capillary blood glucose: 80 to 130 mg/dL (more or less stringent goals may be appropriate based on patient-specific characteristics).

Peak postprandial capillary blood glucose (~1 to 2 hours after a meal): <180 mg/dL (more or less stringent goals may be appropriate based on patient-specific characteristics).

Older adults (≥65 years of age) (ADA 2021):

Note: Consider less strict targets in patients who are using insulin and/or insulin secretagogues (sulfonylureas, meglitinides) (ES [LeRoith 2019]).

HbA1c: <7% to 7.5% (healthy); <8% to 8.5% (complex/intermediate health). Note: Individualization may be appropriate based on patient and caregiver preferences and/or presence of cognitive impairment. In patients with very complex or poor health (ie, limited remaining life expectancy), consider making therapy decisions based on avoidance of hypoglycemia and symptomatic hyperglycemia rather than HbA1c level.

Preprandial capillary blood glucose: 80 to 130 mg/dL (healthy); 90 to 150 mg/dL (complex/intermediate health); 100 to 180 mg/dL (very complex/poor health).

Bedtime capillary blood glucose: 80 to 180 mg/dL (healthy); 100 to 180 mg/dL (complex/intermediate health); 110 to 200 mg/dL (very complex/poor health).

Classification of hypoglycemia (ADA 2021):

Level 1: 54 to 70 mg/dL; hypoglycemia alert value; initiate fast-acting carbohydrate (eg, glucose) treatment.

Level 2: <54 mg/dL; threshold for neuroglycopenic symptoms; requires immediate action.

Level 3: Hypoglycemia associated with a severe event characterized by altered mental and/or physical status requiring assistance.

Mechanism of Action

By inhibiting sodium-glucose cotransporter 2 (SGLT2) in the proximal renal tubules, dapagliflozin reduces reabsorption of filtered glucose from the tubular lumen and lowers the renal threshold for glucose (RTG). SGLT2 is the main site of filtered glucose reabsorption; reduction of filtered glucose reabsorption and lowering of RTG result in increased urinary excretion of glucose, thereby reducing plasma glucose concentrations. Dapagliflozin also reduces sodium reabsorption and increases sodium delivery to the distal tubule, which may decrease cardiac preload/afterload, downregulate sympathetic activity, and decrease intraglomerular pressure.

Pharmacokinetics

Duration: Following discontinuation, urinary glucose excretion returns to baseline within ~3 days for the 10 mg dose.

Protein binding: ~91%.

Metabolism: Primarily mediated by UGT1A9 to an inactive metabolite (dapagliflozin 3-O-glucuronide); CYP-mediated metabolism (minor).

Bioavailability: 78%.

Half-life elimination: ~12.9 hours.

Time to peak, plasma: 2 hours.

Excretion: Urine (75%; <2% as parent drug); feces (21%; ~15% as parent drug).

Pharmacokinetics: Additional Considerations

Altered kidney function: Patients with mild, moderate, or severe impairment had higher systemic exposure compared to patients with normal renal function.

Hepatic function impairment: In patients with severe impairment (Child-Pugh class C), mean Cmax and AUC were increased up to 40% and 67%, respectively.

Pricing: US

Tablets (Farxiga Oral)

5 mg (per each): $21.95

10 mg (per each): $21.95

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Brand Names: International
  • Daflozin (BD);
  • Dapaglip (BD);
  • Daparol (BD);
  • Dapazin (BD);
  • Diglifloz (EG);
  • Edistride (CZ, ES, GR, HR, IE, NL, PL);
  • Forxiga (AE, AR, AT, AU, BE, BH, BR, CH, CL, CN, CO, CR, CY, CZ, DE, DK, DO, EE, EG, ES, FI, GB, GR, GT, HK, HN, HR, HU, ID, IE, IL, IN, IS, JP, KR, KW, LB, LT, LU, LV, MT, MX, MY, NI, NL, NO, NZ, PA, PH, PL, PT, RO, RU, SE, SG, SI, SK, SV, TH, TR, TW, UA, VN, ZW);
  • Sabaglifozin (EG);
  • Zegapets (EG)


For country code abbreviations (show table)
  1. Alexopoulos AS, Blair R, Peters AL. Management of preexisting diabetes in pregnancy: a review. JAMA. 2019;321(18):1811-1819. doi:10.1001/jama.2019.4981 [PubMed 31087027]
  2. American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin No. 190: Gestational diabetes mellitus. Obstet Gynecol. 2018;131(2):e49-e64. [PubMed 29370047]
  3. American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin No. 201: Pregestational diabetes mellitus. Obstet Gynecol. 2018;132(6):e228-e248. doi:10.1097/AOG.0000000000002960 [PubMed 30461693]
  4. American Diabetes Association (ADA). Standards of medical care in diabetes–2021. Diabetes Care. 2021;44(suppl 1):S1-S232. https://care.diabetesjournals.org/content/44/Supplement_1. Accessed January 13, 2021.
  5. Arakaki RF. Sodium-glucose cotransporter-2 inhibitors and genital and urinary tract infections in type 2 diabetes. Postgrad Med. 2016;128(4):409-417. doi:10.1080/00325481.2016.1167570 [PubMed 26982554]
  6. Arnott C, Huang Y, Neuen BL, et al. The effect of canagliflozin on amputation risk in the CANVAS program and the CREDENCE trial. Diabetes Obes Metab. 2020;22(10):1753-1766. doi:10.1111/dom.14091 [PubMed 32436638]
  7. Based on expert opinion.
  8. Bersoff-Matcha SJ, Chamberlain C, Cao C, Kortepeter C, Chong WH. Fournier gangrene associated with sodium-glucose cotransporter-2 inhibitors: A review of spontaneous postmarketing cases. Ann Intern Med. 2019;170(11):764-769. doi:10.7326/M19-0085 [PubMed 31060053]
  9. Blau JE, Tella SH, Taylor SI, Rother KI. Ketoacidosis associated with SGLT2 inhibitor treatment: Analysis of FAERS data. Diabetes Metab Res Rev. 2017;33(8):10.1002/dmrr.2924. doi:10.1002/dmrr.2924 [PubMed 28736981]
  10. Blumenthal KG, Peter JG, Trubiano JA, Phillips EJ. Antibiotic allergy. Lancet. 2019;393(10167):183-198. doi:10.1016/S0140-6736(18)32218-9 [PubMed 30558872]
  11. Blumer I, Hadar E, Hadden DR, et al. Diabetes and pregnancy: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013;98(11):4227-4249. doi:10.1210/jc.2013-2465 [PubMed 24194617 ]
  12. Bobart SA, Gleason B, Martinez N, Norris K, Williams SF. Euglycemic ketoacidosis caused by sodium-glucose cotransporter 2 inhibitors: a case report. Ann Intern Med. 2016;165(7):530-532. doi:10.7326/L15-0535 [PubMed 27699391]
  13. Borlaug BA, Colucci WS. Treatment and prognosis of heart failure with preserved ejection fraction. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed March 11, 2022.
  14. Cahn A, Raz I, Bonaca M, et al. Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE-TIMI 58 study. Diabetes Obes Metab. 2020;22(8):1357-1368. doi:10.1111/dom.14041 [PubMed 32239659]
  15. Colucci WS, Gottlieb SS, Dardas TF. Secondary pharmacologic therapy in heart failure with reduced ejection fraction (HFrEF) in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed April 26, 2021.
  16. Danne T, Garg S, Peters AL, et al. International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium-glucose cotransporter (SGLT) inhibitors. Diabetes Care. 2019;42(6):1147-1154. doi:10.2337/dc18-2316 [PubMed 30728224]
  17. Dave CV, Schneeweiss S, Patorno E. Comparative risk of genital infections associated with sodium-glucose co-transporter-2 inhibitors. Diabetes Obes Metab. 2019;21(2):434-438. doi:10.1111/dom.13531 [PubMed 30207042]
  18. DeSantis A. Sodium-glucose co-transporter 2 inhibitors for the treatment of hyperglycemia in type 2 diabetes mellitus. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed December 8, 2020.
  19. Dizon S, Keely EJ, Malcolm J, Arnaout A. Insights Into the recognition and management of SGLT2-inhibitor-associated ketoacidosis: It's not just euglycemic diabetic ketoacidosis. Can J Diabetes. 2017;41(5):499-503. doi:10.1016/j.jcjd.2017.05.004 [PubMed 28797889]
  20. Egan AM, Dow ML, Vella A. A Review of the pathophysiology and management of diabetes in pregnancy. Mayo Clin Proc. 2020;95(12):2734-2746. doi:10.1016/j.mayocp.2020.02.019 [PubMed 32736942]
  21. Elbeddini A, Tayefehchamani Y, Davey M, et al. Fournier's gangrene with dapagliflozin in a rural hospital: a case report. BMJ Case Rep. 2021;14(2):e237784. doi:10.1136/bcr-2020-237784 [PubMed 33526523]
  22. Engelhardt K, Ferguson M, Rosselli JL. Prevention and management of genital mycotic infections in the setting of sodium-glucose cotransporter 2 inhibitors. Ann Pharmacother. 2021;55(4):543-548. doi:10.1177/1060028020951928 [PubMed 32808541]
  23. Farxiga (dapagliflozin) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; July 2022.
  24. FDA Drug Safety Communication: FDA confirms increased risk of leg and foot amputations with diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR). Food and Drug Administration website. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-confirms-increased-risk-leg-and-foot-amputations-diabetes-medicine. Published May 26, 2017. Accessed October 2021.
  25. FDA Drug Safety Communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. Food and Drug Administration website. http://www.fda.gov/Drugs/DrugSafety/ucm475463.htm. Published December 4, 2015. Accessed October 2021.
  26. FDA Drug Safety Communication: FDA Drug Safety Communication: FDA strengthens kidney warnings for diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR). Food and Drug Administration website. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-strengthens-kidney-warnings-diabetes-medicines-canagliflozin. Published June 14, 2016. Accessed October 2021.
  27. FDA Drug Safety Communication: FDA Drug Safety Communication: FDA warns about rare occurrences of a serious infection of the genital area with SGLT2 inhibitors for diabetes. Food and Drug Administration website. https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-rare-occurrences-serious-infection-genital-area-sglt2-inhibitors-diabetes. Published August 29, 2018. Accessed October 2021.
  28. Fioretto P, Del Prato S, Buse JB, et al; DERIVE Study Investigators. Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study [published correction appears in: Diabetes Obes Metab. 2019;21(1):203]. Diabetes Obes Metab. 2018;20(11):2532-2540. doi:10.1111/dom.13413 [PubMed 29888547]
  29. Fitchett D. A safety update on sodium glucose co-transporter 2 inhibitors. Diabetes Obes Metab. 2019;21 Suppl 2:34-42. doi:10.1111/dom.13611 [PubMed 31081590]
  30. Fralick M, Kim SC, Schneeweiss S, Everett BM, Glynn RJ, Patorno E. Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study. BMJ. 2020;370:m2812. doi:10.1136/bmj.m2812 [PubMed 32843476]
  31. Garber AJ, Handelsman Y, Grunberger G, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2020 executive summary. Endocr Pract. 2020;26(1):107-139. doi:10.4158/CS-2019-0472 [PubMed 32022600]
  32. Geerlings S, Fonseca V, Castro-Diaz D, List J, Parikh S. Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria. Diabetes Res Clin Pract. 2014;103(3):373-381. doi:10.1016/j.diabres.2013.12.052 [PubMed 24529566]
  33. Gilbert RE, Thorpe KE. Acute kidney injury with sodium-glucose co-transporter-2 inhibitors: A meta-analysis of cardiovascular outcome trials. Diabetes Obes Metab. 2019;21(8):1996-2000. doi:10.1111/dom.13754 [PubMed 31050116]
  34. Hahn K, Ejaz AA, Kanbay M, Lanaspa MA, Johnson RJ. Acute kidney injury from SGLT2 inhibitors: potential mechanisms. Nat Rev Nephrol. 2016;12(12):711-712. doi:10.1038/nrneph.2016.159 [PubMed 27847389]
  35. Handelsman Y, Henry RR, Bloomgarden ZT, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on the Association of SGLT-2 Inhibitors and Diabetic Ketoacidosis. Endocr Pract. 2016;22(6):753-762. doi:10.4158/EP161292.PS [PubMed 27082665]
  36. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al; DAPA-CKD Trial Committees and Investigators. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436-1446. doi:10.1056/NEJMoa2024816 [PubMed 32970396]
  37. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063 [PubMed 35363499]
  38. Jabbour S, Seufert J, Scheen A, Bailey CJ, Karup C, Langkilde AM. Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials. Diabetes Obes Metab. 2018;20(3):620-628. doi:10.1111/dom.13124 [PubMed 28950419]
  39. Johnsson K, Johnsson E, Mansfield TA, Yavin Y, Ptaszynska A, Parikh SJ. Osmotic diuresis with SGLT2 inhibition: analysis of events related to volume reduction in dapagliflozin clinical trials. Postgrad Med. 2016;128(4):346-355. doi:10.1080/00325481.2016.1153941 [PubMed 26878357]
  40. Jongs N, Chertow GM, Greene T, et al. Correlates and consequences of an acute change in eGFR in response to the SGLT2 inhibitor dapagliflozin in patients with CKD. J Am Soc Nephrol. 2022;ASN.2022030306. doi:10.1681/ASN.2022030306 [PubMed 35977807]
  41. Khouri C, Cracowski JL, Roustit M. SGLT-2 inhibitors and the risk of lower-limb amputation: Is this a class effect? Diabetes Obes Metab. 2018;20(6):1531-1534. doi:10.1111/dom.13255 [PubMed 29430814]
  42. Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2020;98(4S):S1-S115. [PubMed 32998798]
  43. Kohan DE, Fioretto P, Tang W, List JF. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 2014;85(4):962-971. doi:10.1038/ki.2013.356 [PubMed 24067431]
  44. Leader R, Cowen J, Rajeev SP. Republished: Dapagliflozin (SGLT2-i) induced euglycaemic diabetic ketoacidosis. Drug Ther Bull. 2020;58(4):60-63. doi:10.1136/dtb.2019.231104rep [PubMed 31784467]
  45. LeRoith D, Biessels GJ, Braithwaite SS, et al. Treatment of diabetes in older adults: an Endocrine Society* clinical practice guideline. J Clin Endocrinol Metab. 2019;104(5):1520-1574. doi:10.1210/jc.2019-00198 [PubMed 30903688]
  46. Levine JA, Ann Lo A, Wallia A, Rogers M, VanWagner LB. Dapagliflozin-induced acute-on-chronic liver injury. ACG Case Rep J. 2016;3(4):e169. doi:10.14309/crj.2016.142 [PubMed 28008402]
  47. Li D, Wang T, Shen S, Fang Z, Dong Y, Tang H. Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2017;19(3):348-355. doi:10.1111/dom.12825 [PubMed 27862830]
  48. Marques Vidas M, Dura Gurpide B, Rubio E, Huerta A, Portolés Pérez J. Dapagliflozin-induced hypercalcemia. Hipercalcemia inducida por dapagliflozina. Nefrologia (Engl Ed). 2018;38(3):336-337. doi:10.1016/j.nefro.2017.06.009 [PubMed 28778537]
  49. Matthews DR, Li Q, Perkovic V, et al. Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program. Diabetologia. 2019;62(6):926-938. doi:10.1007/s00125-019-4839-8 [PubMed 30868176]
  50. Mattis DM, Limova M, Mully T. Dapagliflozin-induced sweet syndrome. Cutis. 2019;104(2):E22-E24. [PubMed 31603973]
  51. Mazidi M, Rezaie P, Gao HK, Kengne AP. Effect of sodium-glucose cotransport-2 inhibitors on blood pressure in people with type 2 diabetes mellitus: A systematic review and meta-analysis of 43 randomized control trials with 22 528 patients. J Am Heart Assoc. 2017 May 25;6(6):e004007. doi:10.1161/JAHA.116.004007 [PubMed 28546454]
  52. McMurray JJV, Solomon SD, Inzucchi SE, et al; DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995-2008. doi:10.1056/NEJMoa1911303 [PubMed 31535829]
  53. Mechanick JI, Apovian C, Brethauer S, et al. Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures - 2019 update: cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, the Obesity Society, American Society for Metabolic & Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists. Surg Obes Relat Dis. 2020;16(2):175-247. doi:10.1016/j.soard.2019.10.025 [PubMed 31917200]
  54. Melissas J, Leventi A, Klinaki I, et al. Alterations of global gastrointestinal motility after sleeve gastrectomy: a prospective study. Ann Surg. 2013;258(6):976-982. doi:10.1097/SLA.0b013e3182774522 [PubMed 23160151]
  55. Mellander A, Billger M, Johnsson E, Träff AK, Yoshida S, Johnsson K. Hypersensitivity events, including potentially hypersensitivity-related skin events, with dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis. Clin Drug Investig. 2016;36(11):925-933. doi:10.1007/s40261-016-0438-3 [PubMed 27461213]
  56. Nassif ME, Windsor SL, Borlaug BA, et al. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nat Med. 2021;27(11):1954-1960. doi:10.1038/s41591-021-01536-x [PubMed 34711976]
  57. Neal B, Perkovic V, Mahaffey KW, et al; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644-657. doi:10.1056/NEJMoa1611925 [PubMed 28605608]
  58. Neuen BL, Young T, Heerspink HJL, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis [published correction appears in Lancet Diabetes Endocrinol. 2019;7(12):e23]. Lancet Diabetes Endocrinol. 2019;7(11):845-854. doi:10.1016/S2213-8587(19)30256-6 [PubMed 31495651]
  59. Nichols GA, Brodovicz KG, Kimes TM, Déruaz-Luyet A, Bartels DB. Prevalence and incidence of urinary tract and genital infections among patients with and without type 2 diabetes. J Diabetes Complications. 2017;31(11):1587-1591. doi:10.1016/j.jdiacomp.2017.07.018 [PubMed 28888425]
  60. Nussberger J, Cugno M, Amstutz C, Cicardi M, Pellacani A, Agostoni A. Plasma bradykinin in angio-oedema. Lancet. 1998;351(9117):1693-1697. doi:10.1016/S0140-6736(97)09137-X [PubMed 9734886]
  61. Nyirjesy P, Sobel JD. Genital mycotic infections in patients with diabetes. Postgrad Med. 2013;125(3):33-46. doi:10.3810/pgm.2013.05.2650 [PubMed 23748505]
  62. O'Neill J, Fasching A, Pihl L, Patinha D, Franzén S, Palm F. Acute SGLT inhibition normalizes O2 tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats. Am J Physiol Renal Physiol. 2015;309(3):F227-F234. doi:10.1152/ajprenal.00689.2014 [PubMed 26041448]
  63. Perkovic V, Badve SV, Bakris GL. Treatment of diabetic kidney disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed November 3, 2020.
  64. Pleros C, Stamataki E, Papadaki A, et al. Dapagliflozin as a cause of acute tubular necrosis with heavy consequences: a case report. CEN Case Rep. 2018;7(1):17-20. doi:10.1007/s13730-017-0283-0 [PubMed 29127652]
  65. Reader D, Franz MJ. Lactation, diabetes, and nutrition recommendations. Curr Diab Rep. 2004;4(5):370-376. [PubMed 15461903]
  66. Reed JW. Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure. Vasc Health Risk Manag. 2016;12:393-405. doi:10.2147/VHRM.S111991 [PubMed 27822054]
  67. Refer to manufacturer's labeling.
  68. Rosenstock J, Ferrannini E. Euglycemic diabetic ketoacidosis: A predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care. 2015;38(9):1638-1642. doi:10.2337/dc15-1380 [PubMed 26294774]
  69. Ruanpeng D, Ungprasert P, Sangtian J, Harindhanavudhi T. Sodium-glucose cotransporter 2 (SGLT2) inhibitors and fracture risk in patients with type 2 diabetes mellitus: A meta-analysis. Diabetes Metab Res Rev. 2017;33(6). doi:10.1002/dmrr.2903 [PubMed 28440590]
  70. Schaefer-Graf UM, Hartmann R, Pawliczak J, et al. Association of breast-feeding and early childhood overweight in children from mothers with gestational diabetes mellitus. Diabetes Care. 2006;29(5):1105-1107. [PubMed 16644645]
  71. Sujanani SM, Elfishawi MM, Zarghamravanbaksh P, Castillo FJC, Reich DM. Dapagliflozin-induced acute pancreatitis: a case report and review of literature. Case Rep Endocrinol. 2020;2020:6724504. doi:10.1155/2020/6724504 [PubMed 32123591]
  72. Tang HL, Li DD, Zhang JJ, et al. Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2016;18(12):1199-1206. doi:10.1111/dom.12742 [PubMed 27407013]
  73. Tang H, Li D, Zhang J, et al. Sodium-glucose co-transporter-2 inhibitors and risk of adverse renal outcomes among patients with type 2 diabetes: A network and cumulative meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2017;19(8):1106-1115. doi:10.1111/dom.12917 [PubMed 28240446]
  74. Taylor SI, Blau JE, Rother KI. SGLT2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metab. 2015;100(8):2849-2852. doi:10.1210/jc.2015-1884 [PubMed 26086329]
  75. Toulis KA, Bilezikian JP, Thomas GN, et al. Initiation of dapagliflozin and treatment-emergent fractures. Diabetes Obes Metab. 2018;20(4):1070-1074. doi:10.1111/dom.13176 [PubMed 29193543]
  76. van Niekerk C, Wallace J, Takata M, Yu R. Euglycaemic diabetic ketoacidosis in bariatric surgery patients with type 2 diabetes taking canagliflozin [published online August 20, 2018]. BMJ Case Rep. doi:10.1136/bcr-2017-221527 [PubMed 30131409]
  77. Wexler DJ. Management of persistent hyperglycemia in type 2 diabetes mellitus. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed September 18, 2020.
  78. Wiviott SD, Raz I, Bonaca MP, et al; DECLARE–TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347-357. doi:10.1056/NEJMoa1812389 [PubMed 30415602]
  79. Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393(10166):31-39. doi:10.1016/S0140-6736(18)32590-X [PubMed 30424892]
Topic 93383 Version 245.0